Galectin-3: A modifiable risk factor in heart failure

Rudolf A. De Boer, A. Rogier Van Der Velde, Christian Mueller, Dirk J. Van Veldhuisen, Stefan D. Anker, W. Frank Peacock, Kirkwood F. Adams, Alan Maisel

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Myocardial galectin-3 is upregulated upon cardiac stressors such as angiotensin II and pressure overload leading to cardiac remodeling and heart failure. The expression level of galectin-3 mirrors the progression and severity of heart failure and therefore, galectin-3 is being used as a biomarker for heart failure. However, as galectin-3 is causally involved in pathological myocardial fibrosis it has been suggested that galectin-3 also actively contributes to heart failure development. In this review we discuss how galectin-3 could be a target for therapy in heart failure. Currently, attempts are being made to target or inhibit galectin-3 using natural or pharmaceutical inhibitors with the aim to ameliorate heart failure. Available experimental evidence suggests that galectin-3 inhibition indeed may represent a novel tool to treat heart failure. A strong interaction with aldosterone, another strong pro-fibrotic factor, has been described. Clinical studies are needed to prove if galectin-3 may be used to install specific treatment regimens.

Original languageEnglish
Pages (from-to)237-246
Number of pages10
JournalCardiovascular Drugs and Therapy
Volume28
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Galectin 3
Heart Failure
Aldosterone
Angiotensin II
Fibrosis
Biomarkers
Pressure

Keywords

  • Biomarker
  • Cardiac remodeling
  • Fibrosis
  • Galectin-3
  • Heart failure

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine
  • Pharmacology
  • Medicine(all)

Cite this

De Boer, R. A., Van Der Velde, A. R., Mueller, C., Van Veldhuisen, D. J., Anker, S. D., Peacock, W. F., ... Maisel, A. (2014). Galectin-3: A modifiable risk factor in heart failure. Cardiovascular Drugs and Therapy, 28(3), 237-246. https://doi.org/10.1007/s10557-014-6520-2

Galectin-3 : A modifiable risk factor in heart failure. / De Boer, Rudolf A.; Van Der Velde, A. Rogier; Mueller, Christian; Van Veldhuisen, Dirk J.; Anker, Stefan D.; Peacock, W. Frank; Adams, Kirkwood F.; Maisel, Alan.

In: Cardiovascular Drugs and Therapy, Vol. 28, No. 3, 2014, p. 237-246.

Research output: Contribution to journalArticle

De Boer, RA, Van Der Velde, AR, Mueller, C, Van Veldhuisen, DJ, Anker, SD, Peacock, WF, Adams, KF & Maisel, A 2014, 'Galectin-3: A modifiable risk factor in heart failure', Cardiovascular Drugs and Therapy, vol. 28, no. 3, pp. 237-246. https://doi.org/10.1007/s10557-014-6520-2
De Boer RA, Van Der Velde AR, Mueller C, Van Veldhuisen DJ, Anker SD, Peacock WF et al. Galectin-3: A modifiable risk factor in heart failure. Cardiovascular Drugs and Therapy. 2014;28(3):237-246. https://doi.org/10.1007/s10557-014-6520-2
De Boer, Rudolf A. ; Van Der Velde, A. Rogier ; Mueller, Christian ; Van Veldhuisen, Dirk J. ; Anker, Stefan D. ; Peacock, W. Frank ; Adams, Kirkwood F. ; Maisel, Alan. / Galectin-3 : A modifiable risk factor in heart failure. In: Cardiovascular Drugs and Therapy. 2014 ; Vol. 28, No. 3. pp. 237-246.
@article{6565dae51f334f8c9cabe913559d7be5,
title = "Galectin-3: A modifiable risk factor in heart failure",
abstract = "Myocardial galectin-3 is upregulated upon cardiac stressors such as angiotensin II and pressure overload leading to cardiac remodeling and heart failure. The expression level of galectin-3 mirrors the progression and severity of heart failure and therefore, galectin-3 is being used as a biomarker for heart failure. However, as galectin-3 is causally involved in pathological myocardial fibrosis it has been suggested that galectin-3 also actively contributes to heart failure development. In this review we discuss how galectin-3 could be a target for therapy in heart failure. Currently, attempts are being made to target or inhibit galectin-3 using natural or pharmaceutical inhibitors with the aim to ameliorate heart failure. Available experimental evidence suggests that galectin-3 inhibition indeed may represent a novel tool to treat heart failure. A strong interaction with aldosterone, another strong pro-fibrotic factor, has been described. Clinical studies are needed to prove if galectin-3 may be used to install specific treatment regimens.",
keywords = "Biomarker, Cardiac remodeling, Fibrosis, Galectin-3, Heart failure",
author = "{De Boer}, {Rudolf A.} and {Van Der Velde}, {A. Rogier} and Christian Mueller and {Van Veldhuisen}, {Dirk J.} and Anker, {Stefan D.} and Peacock, {W. Frank} and Adams, {Kirkwood F.} and Alan Maisel",
year = "2014",
doi = "10.1007/s10557-014-6520-2",
language = "English",
volume = "28",
pages = "237--246",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Galectin-3

T2 - A modifiable risk factor in heart failure

AU - De Boer, Rudolf A.

AU - Van Der Velde, A. Rogier

AU - Mueller, Christian

AU - Van Veldhuisen, Dirk J.

AU - Anker, Stefan D.

AU - Peacock, W. Frank

AU - Adams, Kirkwood F.

AU - Maisel, Alan

PY - 2014

Y1 - 2014

N2 - Myocardial galectin-3 is upregulated upon cardiac stressors such as angiotensin II and pressure overload leading to cardiac remodeling and heart failure. The expression level of galectin-3 mirrors the progression and severity of heart failure and therefore, galectin-3 is being used as a biomarker for heart failure. However, as galectin-3 is causally involved in pathological myocardial fibrosis it has been suggested that galectin-3 also actively contributes to heart failure development. In this review we discuss how galectin-3 could be a target for therapy in heart failure. Currently, attempts are being made to target or inhibit galectin-3 using natural or pharmaceutical inhibitors with the aim to ameliorate heart failure. Available experimental evidence suggests that galectin-3 inhibition indeed may represent a novel tool to treat heart failure. A strong interaction with aldosterone, another strong pro-fibrotic factor, has been described. Clinical studies are needed to prove if galectin-3 may be used to install specific treatment regimens.

AB - Myocardial galectin-3 is upregulated upon cardiac stressors such as angiotensin II and pressure overload leading to cardiac remodeling and heart failure. The expression level of galectin-3 mirrors the progression and severity of heart failure and therefore, galectin-3 is being used as a biomarker for heart failure. However, as galectin-3 is causally involved in pathological myocardial fibrosis it has been suggested that galectin-3 also actively contributes to heart failure development. In this review we discuss how galectin-3 could be a target for therapy in heart failure. Currently, attempts are being made to target or inhibit galectin-3 using natural or pharmaceutical inhibitors with the aim to ameliorate heart failure. Available experimental evidence suggests that galectin-3 inhibition indeed may represent a novel tool to treat heart failure. A strong interaction with aldosterone, another strong pro-fibrotic factor, has been described. Clinical studies are needed to prove if galectin-3 may be used to install specific treatment regimens.

KW - Biomarker

KW - Cardiac remodeling

KW - Fibrosis

KW - Galectin-3

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=84903778833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903778833&partnerID=8YFLogxK

U2 - 10.1007/s10557-014-6520-2

DO - 10.1007/s10557-014-6520-2

M3 - Article

C2 - 24789662

AN - SCOPUS:84903778833

VL - 28

SP - 237

EP - 246

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 3

ER -